NeuroMetrix Showcases Quell Technology at the Midwest Podiatry Conference

WALTHAM, Mass.--(BUSINESS WIRE)--

NeuroMetrix, Inc. NURO today announced that Quell^® Wearable Pain Relief Technology^™ will be featured at the Midwest Podiatry Conference to be held March 31-April 3 at the Hyatt Regency Chicago.

"Podiatrists are at the front lines in treating chronic pain, with 77% of American adults suffering from foot pain," says Frank McGillin, Senior Vice President and General Manager, Consumer of NeuroMetrix. "Every day we see more and more healthcare professionals integrating Quell's 100% drug free technology into their treatment protocols. Quell was recently awarded the American Podiatric Medical Association (APMA) Seal of Approval, which helps podiatrists feel confident that they are offering patients an innovative, clinically proven way to manage their chronic pain."

About Quell

Quell utilizes NeuroMetrix's patented neurostimulation technology to provide widespread relief from chronic pain. The advanced wearable device is lightweight and can be worn during the day while active, and at night while sleeping. It has been cleared by the FDA for treatment of chronic pain without a prescription. In a recent study, 81% of Quell users reported an improvement in their chronic pain. Quell includes a smartphone app that tracks and personalizes their pain therapy. It is available for purchase at QuellRelief.com, selected retailers and healthcare professionals.

About NeuroMetrix

NeuroMetrix is an innovative healthcare company that develops wearable medical technology and point-of-care tests that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders. The company is located in Waltham, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996. For more information, please visit www.NeuroMetrix.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160328005480/en/